SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cellyan Biotechnology Co., Ltd (HKPD) has a negative trailing P/E of -178.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -0.56%.
Criteria proven by this page:
- VALUE (53/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Trailing Earnings Yield -0.56% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Overall SharesGrow Score: 42/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
53/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HKPD
Valuation Multiples
P/E (TTM)-178.7
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.97
P/S Ratio0.29
EV/EBITDA6.2
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.55
Revenue / Share$2.25
FCF / Share$0.05
Yields & Fair Value
Earnings Yield-0.56%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2023 |
31.1 |
0.00 |
53.00 |
2.47 |
- |
| 2024 |
15.6 |
0.16 |
4.88 |
1.24 |
- |
| 2025 |
-360.1 |
3.55 |
1.95 |
0.48 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$0.09 |
$12.56M |
$998.2K |
7.9% |
| 2023 |
$0.00 |
$16.69M |
$1.33M |
8% |
| 2025 |
$0.00 |
$20.31M |
$-27.06K |
-0.1% |
